Medications. New medications, old medications, you’re probably tired of hearing about all the medications there are out there, and we don’t want to take you on another loop, but things are looking pretty good for those that are affected by rheumatoid arthritis. The drug tofacitinib developed by pharmaceutical giant Pfizer Inc. has achieved its goals in Phase III (one of the end stages in a study) among patients with rheumatoid arthritis. Some things to note about Pfizer Inc. are that it is a global pharmaceutical company and ranks number one in sales around the world; their products include Viagara, Advil, and Lipitor. So it seems like Pfizer Inc. has a pretty impressive portfolio, and that this medication may be the real deal.
What’s so good about this new medication, tofacitinib? Well, not only is tofacitinib Pfizer’s latest blockbuster prospect (not to make it sound like it’s their cash cow) but this drug has demonstrated some promising results. It’s a drug that is currently under investigation for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease (IBD), and other immunological diseases. Furthermore, tofacitinib hits the mark on reducing the physical symptoms of rheumatoid arthritis including swelling and sore joints. We’ll spare you the details on how it works, but if you really want to know you can leave us a comment below.
Perfect! But when is it available? Well, there are currently four other trials for tofacitinib, and the results are expected by the middle of this year. Furthermore, it is expected that it will win regulatory approval by next year in the United States, but it’s not sure when it will come to Canada. However, there are some questions that are looming 1) How does this drug measure against other therapies? 2) Are there other medications available for treatment of psoriasis, IBD and other immunological diseases that tofacitinib was under investigation for?
There is currently one medication being investigated at the Canadian Centre for Clinical Trials for psoriatic arthritis. The study medication, apremilast, is an oral and may one day be a treatment option for those suffering from psoriatic arthritis. For more information or to see if you are eligible for any of our other trials, please visit: